Immunovant, Inc.
Immunovant is a clinical-stage immunology company and a trailblazer in anti-FcRn technology, developing targeted therapies that reduce harmful immunoglobulin G autoantibodies to enable normal lives for people with autoimmune diseases. Its lead investigational product, imeroprubart (IMVT-1402), is a fully human monoclonal antibody advancing across multiple autoimmune indications.
Company Info
Sector:Biotechnology
Headquarters:Durham, North Carolina, United States
Founded:2018
Website:www.immunovant.com/
Upcoming Milestones & Key Dates
2026-2027
Clinical Readout
Phase 3 readouts for imeroprubart across autoimmune indications
2027
Regulatory Milestone
Potential regulatory filings for imeroprubart
Clinical Development Pipeline
imeroprubart (IMVT-1402)
Target: Neonatal Fc receptor (FcRn)batoclimab (IMVT-1401)
Target: Neonatal Fc receptor (FcRn)IMVT-1402
Target: Neonatal Fc receptor (FcRn)Recent News
No recent news updates available for this company.
Leadership Team
Eric Venker, MD, PharmD
Chief Executive Officer
Tiago Girão
Chief Financial Officer
Jay S. Stout, PhD, MS
Chief Technology Officer